Introduction
Homozygous familial hypercholesterolaemia (FH) is a rare disorder resulting from bi-allelic mutations of genes encoding the LDL receptor (LDLR), 1 apolipoprotein B (apoB), proprotein convertase subtilisin/kexin type 9 (PCSK9), or the LDL receptor adaptor protein (LDL-RAP 1). 2 The consequent diminution in LDL receptor activity leads to extreme elevations of LDL cholesterol from birth, accelerated atherosclerosis, and premature death from acute coronary syndromes, often associated with valvar and supravalvar atheroma of the aortic root. 3, 4 If untreated, the average age of death is 18 years, 5, 6 although deaths before the age of 5 years are recorded. 7 There have been no randomized clinical trials of lipid-lowering therapy, although observational studies suggest the latter is beneficial. 5, 6, 8 pheresis at weekly or fortnightly intervals significantly increased the longevity of homozygotes but the numbers were small. 5 After 1980, non-selective plasmapheresis was mostly replaced by selective extracorporeal removal of atherogenic lipoproteins, collectively termed lipoprotein (or LDL) apheresis. This is currently recommended in the UK, Europe, and the USA, for the treatment of homozygotes insufficiently responsive to high doses of statins and ezetimibe. 2, 10, 11 Recently, two retrospective surveys described outcomes in 149 FH homozygotes in South Africa 6 and 44 in the UK. 12 In both surveys, most patients were treated with statins, but plasmapheresis or lipoprotein apheresis was used in 15% of South African patients vs. more than 60% of UK patients. Consequently, serum cholesterol was reduced by only 24% in the South African cohort compared with 45% in UK patients. The risk of death in statin-treated South African homozygotes was one-third that of patients in the pre-statin era, while post hoc analysis of UK homozygotes showed that mortality when on-treatment serum cholesterol was below the median (8.45 mmol/L) was only one-fifth of that if it was above the median. These results suggest that chances of survival in homozygous FH depend upon the extent of reduction in serum cholesterol. To test this hypothesis, we analysed the combined data from South African and UK homozygotes treated with various lipid-lowering measures between 1990 and 2014.
Subjects and methods
Patients with homozygous FH were drawn from the databases of the two retrospective surveys. 6, 12 The study involved 133 patients, 113
in South Africa (Johannesburg 81 and Cape Town 32) and 20 in the UK. Patients were included if they were alive and statin-naive at the start of 1990 and were retrospectively followed up until death or the end of 2014. Three patients were lost to follow up. Criteria for the diagnosis of homozygous FH were confirmation of two mutant alleles at the LDLR or LDL-RAP 1 loci or an untreated LDL cholesterol > _13 mmol/L and cutaneous or tendon xanthomas before the age of 10 years. In 95% of patients, the diagnosis was confirmed by DNA analysis.
LDL receptor mutations were determined as previously described [13] [14] [15] [16] [17] and classified according to the LOVD database. 18 Assignment of LDL receptor status as negative/negative, negative/ defective or defective/defective depended upon measurement of LDL binding by cultured cells or upon the predicted dysfunctional effects of mutations according to site and severity. LDL-RAP 1 mutations (causing autosomal recessive hypercholesterolaemia) were assigned to the defective/defective category because of similar pre-treatment cholesterol levels. One apoB, but no PCSK9, mutation was detected (see Supplementary material online, Table S1 ).
Most patients were treated initially with maximal doses of simvastatin, or atorvastatin (after 1997) or rosuvastatin (after 2003), supplemented with ezetimibe in over 50% of patients from 2004 onwards. Apheresis (from 1990), lomitapide (from 2008), and evolocumab (from 2012) were regarded as treatment if administered regularly and continuously for > _1 year.
Statistical analysis
The objective of the analysis was to investigate the relationship between on-treatment serum total cholesterol (TC) and survival. On-treatment TC values used in the analysis were the average of all the results available in each patient. In those on apheresis the mean pre-procedure values were used.
Patients were divided into three groups based on quartiles of ontreatment serum cholesterol. Quartile 1 contained the lowest values, Quartiles 2 þ 3 the intermediate, and Quartile 4 the highest.
The initial analyses compared the three groups in terms of demographics, pre-treatment cholesterol levels, and medications administered. Continuous variables with a normal distribution were compared using analysis of variance, the Kruskal-Wallis test was used for non-normally distributed variables and the v 2 test or Fisher's exact test for categorical variables.
The following outcomes were compared between groups: death from any cause, death from cardiovascular disease, and fatal plus nonfatal major adverse cardiovascular events (MACE). As these outcomes did not occur in all patients, they were analysed as time-toevent variables. Cox regression was used for the analysis of the death from any cause outcome. For the two other outcomes, there were competing outcomes, which may mean that censoring is informative. For these outcomes, competing risks regression methods were used, as described by Fine and Gray. 19 For cardiac death, non-cardiac deaths were considered as a competing risk, while for MACE, non-cardiac deaths were considered as a competing risk only in patients without MACE (as MACE occurred before death). A series of analyses was performed, comparing outcomes between quartiles, sequentially adjusting for potentially confounding factors as follows:
(i) no adjustments; (ii) patients' demographics only; (iii) analysis 2 plus pre-treatment cholesterol levels; and (iv) analysis 3 plus types of medication used.
Only variables differing between quartiles in the initial analyses (P < 0.1) were included as potential confounding factors. Evolocumab was omitted from the 4th adjustment, because there were no deaths on this medication, which rendered it ineligible for analysis. All analyses were performed using Stata (version 13.1).
Results

Baseline characteristics of patients according to on-treatment serum cholesterol
The 133 patients were subdivided into three quartiles according to their on-treatment serum TC levels as follows: Quartile 1, <8.1 mmol/L; Quartiles 2 þ 3, 8.1-15.1 mmol/L; and Quartile 4, >15.1 mmol/L. Baseline characteristics of patients are shown in Table 1 .
Comparison of treatment sites showed that the majority of UK patients (60%) but only a minority of Johannesburg (20%) and Cape Town patients (16%) were in Quartile 1 (P = 0.003). This reflects the fact that more UK patients were on apheresis than were Johannesburg and Cape Town patients (50% versus 4% and 38%, There were no differences in gender between quartiles, but there were ethnic differences, with a preponderance of Caucasians (91%) and a dearth of Asians (0%) in Quartile 4 compared with Quartile 1 (64% and 18%; P = 0.02).
Over half of the patients in Quartile 4 had null/null or null/defective LDLR mutations, whereas three-quarters of those in Quartiles 1 and 2 þ 3 had defective/defective LDLR or LDLRAP1 mutations (P = 0.01). This was reflected by differences in pre-treatment serum TC and LDL cholesterol levels, which were higher in Quartile 4 compared with Quartiles 1 and 2 þ 3 (P < 0.001). Serum triglyceride, HDL cholesterol, and lipoprotein (a) [Lp(a)] levels did not differ significantly between the quartiles. However, a higher proportion of patients in Quartile 4 than in Quartiles 1 and 2 þ 3 had pre-existing cardiovascular disease (27% vs. 1% and 10%, P = 0Á01).
Treatment details and outcomes
Fourteen (10.5%) homozygotes had a portacaval shunt and 10 (7.5%) had undergone apheresis before 1990, but there were no significant differences between the quartiles in these respects.
As presented in Table 2 , there were slightly but not significantly more patients on apheresis in Quartile 1 and a trend towards more patients on evolocumab (P = 0Á05) and other treatments (P = 0Á07). These included three liver transplants and two patients on lomitapide in Quartile 1, one portocaval shunt and one patient on lomitapide in Quartile 2 þ 3, and one patient on lomitapide in Quartile 4. There were significantly less patients in Quartile 4 on statins (88%) and ezetimibe (33%) compared with Quartiles 1 and 2 þ 3, of whom 100% and 99%, respectively, were on statins (P = 0Á03) and 55% and 67% on ezetimibe (P = 0Á006).
Mean TC levels on treatment were 6.3, 11.6, and 18.5 mmol/L in Quartiles 1, 2 þ 3, and 4, with corresponding reductions from baseline of 58%, 29%, and 10% (P < 0.001). The median (interquartile range) of age at the start of treatment was 15 (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) years with no significant differences between the quartiles.
Just over one-third of the patients died during the 25 years of follow-up. There was a highly significant excess of deaths from all causes (69.7%) and cardiovascular deaths (51.5%) in Quartile 4 compared with Quartiles 2 þ 3 (28.4% and 25.4%) and Quartile 1 (9.1% and 6.1%) (P < 0.001 in each instance). There was also a significant excess of non-cardiovascular or unknown deaths in Quartile 4 (P = 0.02), although the two deaths from unknown causes might have been cardiovascular. The mean age at the end of 2014 or prior death was 31 and did not differ significantly between the quartiles.
Survival analysis
Survival analysis was used to compare outcomes between patients according to their on-treatment serum TC, with increasing adjustments for potentially confounding factors. The hazard ratios derived from the regression analyses are presented in Table 3 . These ratios give the risk of the outcome occurring during follow-up in Quartiles 2 þ 3 and 4 relative to the risk in Quartile 1.
The results for any death (all-cause mortality) show a significant association between on-treatment TC levels and time to death. In each case, the risk was lowest in Quartile 1, and therefore survival times were longer. The unadjusted analysis shows that the risk of death was 11.5 times greater in Quartile 4 relative to Quartile 1 (P < 0.001). This was reduced to 6.2 times greater after adjusting for demographics, pre-treatment cholesterol levels, and treatment differences (P = 0Á04). A graphical illustration of the mortality rates in the three quartiles is shown in Figure 1 . There were no differences in the overall survival of patients according to whether they did or did not undergo apheresis. However, any beneficial effect apheresis may have had would have been obscured by the differences in efficacy of the procedure in the UK and South Africa, illustrated by the fact that 60% of patients on apheresis in the UK were in Quartile 1 of on-treatment TC vs. only 13% of patients on apheresis in South Africa (P = 0.028). The cholesterol level and not the type of mutation determined whether a patient underwent apheresis.
The results for cardiovascular death also showed a significant difference between quartiles when no other factors were considered, the risk in Quartile 4 being 12.8 times higher than Quartile 1 (P < 0.001). After adjusting for patient demographics, and then for pre-treatment TC, the risk was still three to four times higher, but the differences were now of borderline statistical significance. There was no significant difference in risk between the quartiles after additionally adjusting for treatment differences. The results, shown graphically in Figure 2 , demonstrate that differences in cardiovascular mortality mirror those for total mortality.
The third analysis in Table 3 shows the hazard ratios for MACE, the risk being roughly twice as high in Quartile 4 as in Quartile 1 (P = 0.01). The hazard ratios became statistically insignificant after adjustment for confounding factors. For all the three outcomes analysed in Table 3 , the magnitude of hazard ratios for Quartile 2 þ 3 vs.
Quartile 1 was roughly half that of Quartile 4 vs. Quartile 1. However, as illustrated in the Supplementary material online, Figure  S1 , the frequency of MACE was similar in Quartiles 2 þ 3 and 1.
Overall, the commonest types of MACE were coronary artery bypass grafting (n = 50), aortic valve replacement (n = 29), and coronary angioplasty ± stenting (n = 20). Over the course of 25 years, one hapless patient (but fortunate survivor) underwent four coronary angioplasties, two coronary artery bypass procedures, two carotid endarterectomies, an aortic valve replacement, an abdominal aortic graft, and bilateral iliac artery angioplasties. The patient exemplifies both the pan-arterial nature of the atherosclerotic complications of homozygous FH and its medico-economic consequences.
Risk factors for major adverse cardiovascular event
An unadjusted comparison of patients sustaining (n = 79, 59%) or not sustaining (n = 54, 41%) one or more MACEs while on treatment showed that those with a MACE were older (36 vs. 24 years, P = 0.0001), more often Caucasian (83.5% vs. 63Á0%, P = 0.008) and more likely to have pre-existing cardiovascular disease (21.5% vs. 0%, P = 0.0001). They started treatment later (at 21 vs. 10 years of age, P = 0.0001) and had less reduction in TC on treatment (-29% vs. -39%, P = 0.004). There was also a trend towards MACE patients more often having null/null or null/defective LDLR mutations (38% vs. 21%, P = 0.052). However, there were no significant differences in gender between those with and without MACE (males 43% vs. 50%, females 57% vs. 50%) or in their pre-treatment TC (18.4 
Discussion
The severity of hypercholesterolaemia, its therapeutic refractoriness, and likelihood of premature death from the cardiovascular complications of severe aortic root and coronary atherosclerosis have long made homozygous FH a therapeutic challenge. Recent studies suggest, however, that a wider spectrum of phenotypic expression exists than was previously thought, with some genetically proved homozygotes having LDL cholesterol levels well below the current diagnostic threshold of 13 mmol/L. 20 The patients in our survey were 'old school' homozygotes, with pre-treatment TC levels averaging 18 mmol/L. Despite treatment, 34% of them died and nearly 60% suffered a MACE during the 25 years of follow-up. The division of patients into three unequal groups of on-treatment TC replicated the levels seen in clinical practice in (i) a minority of poorly controlled homozygotes (TC >15.1, mean 18.5 mmol/L), (ii) a majority of averagely controlled homozygotes (TC 8.1-15.1, mean 11.6 mmol/L), and (iii) a minority of better controlled homozygotes (TC <8.1, mean 6.3 mmol/L). Demonstrating differences in survival rates between these three groups would clearly have important therapeutic implications.
Our findings confirm the proposition that the risks of death from any cause and from cardiovascular events were determined by the on-treatment level of serum TC, 90% of which is LDL cholesterol in FH homozygotes. The relationship between on-treatment cholesterol and total mortality, which appeared to be exponential rather than linear, remained statistically significant after correction for demographic, lipid-related, and therapeutic differences between patients in the three quartiles of on-treatment cholesterol. A strikingly similar KaplanMeier plot was observed for the relationship between on-treatment cholesterol and cardiovascular mortality, the latter being responsible for 80% of all deaths. The reduction in hazard ratio after correcting for differences in medication would be expected, given the latter's influence in determining on-treatment serum cholesterol and MACE.
Patients sustaining a MACE were older, had more pre-existing cardiovascular disease, started treatment later, and had less reduction in serum cholesterol on treatment than patients without MACE. They were also more likely to be Caucasian and to have severe LDLR mutations. Interestingly, there was no difference in gender or Lp(a) levels between homozygotes sustaining or not sustaining a MACE, which contrasts with the findings in FH heterozygotes. 21, 22 A similar lack of effect of Lp(a) on CV outcomes in homozygotes was recently reported by Bruckert et al.
23
The fact that most UK patients were in the lowest quartile of ontreatment serum cholesterol reflects the greater use of apheresis in the UK, given that most other forms of treatment were similar to those used in South African patients, except that just over 20% of the latter were on evolocumab during the last 2 years of the study and 3% were on lomitapide. The reductions in cholesterol levels in patients on these agents averaged 21% and 46%, respectively. Previous studies of evolocumab 24 have shown that reductions in LDL vary with the residual function of the LDLR, being nil in homozygotes with null/null mutations, whereas the effect of lomitapide is independent of mutational status. 25 The survival analysis showed a strong relationship between clinical benefit and the extent of lowering of TC and therefore of LDL cholesterol, irrespective of how this was achieved.
Despite the limitations of our retrospective, multicentre survey (incomplete data retrieval and differing case management protocols), our findings provide convincing evidence that effective lipid-lowering therapy greatly improves survival in homozygous FH. As shown by others, starting treatment early was associated with fewer MACE. 8 The question of the extent to which cholesterol should be lowered to arrest progression of atherosclerosis in FH homozygotes was addressed by the European Atherosclerosis Society (EAS), which specified target levels of LDL cholesterol of <3.5 mmol/L in children and <2.5 mmol/L in adults or <1.8 mmol/L in those at the highest risk. 2, 26 These levels can seldom be achieved with existing apheresis and drug regimens and additional LDL-lowering measures are needed. The most effective, but also the most expensive and most prone to side effects, is the microsomal triglyceride transfer protein (MTP) inhibitor lomitapide. 25 Another option is the antisense oligonucleotide inhibitor of apolipoprotein B synthesis, mipomersen 27 which, like lomitapide, reduces LDL synthesis. Lomitapide is currently licensed in the USA and in Europe. Mipomersen, licensed only in the USA, is less effective than lomitapide in homozygotes and also has safety concerns. 27 Our findings support proposals that in homozygotes failing to achieve target levels of LDL with high-dose statins and ezetimibe, additional therapy is required. 2, 10, 11, 26, 28 The choice will be dictated by the availability, affordability, and risks and benefits of the treatment in question. In addition to lipoprotein apheresis, current options are the PCSK9 inhibitor evolocumab (except in receptor-negative homozygotes) and either lomitapide or mipomersen. We conclude that there is a pressing need to implement this multi-pronged approach more widely if European Atherosclerosis Society/European Society of Cardiology goals for FH are to be achieved. 
